Search

Displaying results 4341 - 4350 of 7063 in total
  1. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.

  2. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.

    Products: ALFUZOSIN 5MG 1A PHARMA, ALFUZOSIN 10MG 1A PHARMA
  3. Drug

    Methotrexate

    go.drugbank.com/drugs/DB00563
    ApprovedInvestigational

    [L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198] … Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.

    Categories: OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: Methotrexate PF/sa Injection, METOTREXATO DOC GENERICI
  4. Drug

    Ceftolozane

    go.drugbank.com/drugs/DB09050
    ApprovedInvestigational

    Ceftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. … [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections.

  5. Drug

    Zucapsaicin

    go.drugbank.com/drugs/DB09120
    ApprovedWithdrawn

    Zucapsaicin, the cis-isomer of capsaicin, is a topical analgesic used to treat osteoarthritis of the knee and other neuropathic pain. … Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.

  6. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]

  7. Drug

    Momelotinib

    go.drugbank.com/drugs/DB11763
    ApprovedInvestigational

    Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.

  8. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis. … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.

  9. Drug

    DP-b99

    go.drugbank.com/drugs/DB05820
    Investigational

    DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment

  10. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Melperone has been used for a span of greater than 30 years in the European Union [L1316]. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].

    Categories: Dopamine D2 Receptor AntagonistsProducts: MELPERON 1A PHARMA 50MG, MELPERON 1A PHARM 25MG/5ML